Literature DB >> 7444141

Ultrastructural study of the cardiotoxicity and light-microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines.

D Dantchev, V Slioussartchouk, M Paintrand, C Bourut, M Hayat, G Mathé.   

Abstract

Golden hamsters were administered seven anthracyclines: adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (eADM), rubidazone (RBZ), aclacinomycin (ACM), and N-trifluoroacetyladriamycin-14-valerate (AD-32), three times a week during 4 weeks, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. We examined their myocardia by electron microscopy (EM) and their skin by light microscopy (LM), and report here the findings of these two examinations. The mortality was very high for the groups of hamsters treated with ADM, DTR, DRB, eADM, and RBZ (all treated hamsters died before the end of the fourth week) and very low for those treated with ACM and AD-32 (for each drug, only one of the 21 treated animals died after 4 weeks of treatment). After the first week of treatment and chiefly after the second week, all treated hamsters, except those treated with ACM, showed very severe EM alterations of their myocardia. EM detected almost no early myocardial lesions in ACM-treated hamsters but, after 4 weeks of treatment, severe cardiac lesions also appeared which, like those after AD-32, were nonlethal and reversible. LM of the skin detected degenerative lesions with atrophy of all epidermic layers and a loss of the hair (alopecia) in all treated hamsters except those treated with ACM and AD-32; the skin in these two groups preserved its normal histologic structure. These observations agree with phase I-II clinical ACM studies in which the rate of ECG abnormalities was 4.5% and the rate of alopecia 0%, and with an early AD-32 clinical study conducted by Blum [3].

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7444141     DOI: 10.1007/978-3-642-81488-4_28

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  4 in total

1.  Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.

Authors:  D A Vorobiof; M Iturralde; G Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?

Authors:  G Mathé; C Jasmin
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  DNA-binding studies of valrubicin as a chemotherapy drug using spectroscopy and electrochemical techniques.

Authors:  Reza Hajian; Parvin Hossaini; Zahra Mehrayin; Pei Meng Woi; Nafiseh Shams
Journal:  J Pharm Anal       Date:  2017-01-11

4.  Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA.

Authors:  Reza Hajian; Zahra Tayebi; Nafiseh Shams
Journal:  J Pharm Anal       Date:  2016-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.